Calithera Biosciences, Inc. (CALA)

Calithera Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	-	9.75	-	-	22.25
Revenue Growth (YoY)	-	-	-	-	-14.26%
Cost of Revenue	28.53	53.46	71.02	76.29	66.2
Gross Profit	-28.53	-43.71	-71.02	-76.29	-43.94
Selling, General & Admin	13.54	20.85	20.37	16.61	13.34
Research & Development	-	50.88	-	-	-
Operating Expenses	13.54	71.73	20.37	16.61	13.34
Operating Income	-42.07	-115.43	-91.39	-92.9	-57.28
Interest Expense	-	-0.02	-	-	-
Interest & Investment Income	0.48	-	1.25	3.04	2.65
Other Non Operating Income (Expenses)	1.95	-	-	-	-
EBT Excluding Unusual Items	-39.65	-115.45	-90.14	-89.86	-54.63
Other Unusual Items	-	0.36	-	-	-
Pretax Income	-39.65	-115.09	-90.14	-89.86	-54.63
Net Income	-39.65	-115.09	-90.14	-89.86	-54.63
Preferred Dividends & Other Adjustments	-18.36	-	-	-	-
Net Income to Common	-21.29	-115.09	-90.14	-89.86	-54.63
Shares Outstanding (Basic)	5	4	3	2	2
Shares Outstanding (Diluted)	5	4	3	2	2
Shares Change (YoY)	35.17%	7.32%	45.46%	29.25%	11.09%
EPS (Basic)	-4.60	-31.16	-26.20	-37.99	-29.85
EPS (Diluted)	-7.94	-31.16	-26.20	-37.99	-29.85
Free Cash Flow	-43.74	-66.45	-84.37	-78.75	-65.06
Free Cash Flow Per Share	-8.76	-17.99	-24.52	-33.29	-35.55
Gross Margin	-	-	-	-	-197.45%
Operating Margin	-	-1183.93%	-	-	-257.40%
Profit Margin	-	-1180.39%	-	-	-245.48%
Free Cash Flow Margin	-	-681.51%	-	-	-292.33%
EBITDA	-41.82	-115.15	-91.02	-92.42	-56.78
EBITDA Margin	-	-	-	-	-255.13%
D&A For EBITDA	0.26	0.28	0.36	0.48	0.51
EBIT	-42.07	-115.43	-91.39	-92.9	-57.28
EBIT Margin	-	-	-	-	-257.40%
Revenue as Reported	-	9.75	-	-	22.25

Updated Mar 31, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.